See the DrugPatentWatch profile for eliquis
Will a generic (or biosimilar) of Eliquis be available in 2026?
Eliquis (apixaban) is not expected to have a “generic in 2026” in most scenarios, because Eliquis is still under active patent and exclusivity protection for key formulations and/or methods that keep lower-cost generic competitors from launching right away. DrugPatentWatch tracks these protections and the likely timing for generic entry. [1]
When does Eliquis’s patent/exclusivity protection typically start to open up?
The exact timing depends on which specific Eliquis patent(s) and exclusivities a potential competitor would need to wait out. DrugPatentWatch consolidates these data points and links out to the underlying patent records so you can see what’s expiring and when generic approval/launch could become feasible. [1]
If there’s no generic in 2026, what about “authorized” or “near-generic” options?
If a true generic launch is delayed by patent or exclusivity barriers, patients and payers may still see options such as:
- switching to an alternative anticoagulant (different active ingredient), or
- access via insurance coverage changes or formulary updates,
but those are not the same as an FDA-approved generic for apixaban.
What does “generic for Eliquis” mean in practice?
For apixaban, “generic” would mean an FDA-approved generic drug (same active ingredient, same dosage form/strength) for Eliquis tablets. In the US, competitors must typically address the relevant patent listings in the FDA Orange Book and meet FDA requirements before marketing.
Where to check the most up-to-date entry date
DrugPatentWatch is the quickest way to verify whether any Eliquis patents/exclusivities are forecast to expire in 2026 (and which ones control generic entry). [1]
Sources:
[1] https://www.drugpatentwatch.com/